NCT03841110 2023-05-01FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsFate TherapeuticsPhase 1 Completed37 enrolled
NCT00006033 2013-05-30Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck CancerNational Cancer Institute (NCI)Phase 2 Completed